Patients with known brain active and untreated metastases should be excluded from this clinical trial
Patients with known brain metastases should be excluded from this clinical trial except as those described below
Primary brain cancers or active CNS metastases should be excluded from this clinical trial
Participants with known untreated brain metastases are excluded from this clinical trial
Participants with known brain metastases should be excluded from this clinical trial
Participants with known brain metastases should be excluded from this clinical trial
Subject with known brain metastases should be excluded from this clinical trial; however, baseline brain imaging is not required prior to enrollment in the study if patients are asymptomatic
Those with known brain metastases should be excluded from this clinical trial
Patients with known brain metastases should be excluded from this clinical trial
Patients with known brain metastases should be excluded from this clinical trial; a scan to confirm the absence of brain metastasis is not required
Patients with known brain metastases will be excluded from this clinical trial
Patients with known brain metastases will be excluded from this clinical trial
Subjects with known brain metastases should be excluded from this clinical trial
Patients with known brain metastases should be excluded from this clinical trial
Subjects with primary brain cancers or active CNS metastases should be excluded from this clinical trial
Patients with known brain metastases should be excluded from this clinical trial
Participants with symptomatic known brain metastases <  weeks from radiation treatment should be excluded from this clinical trial
Patients with known brain metastases should be excluded from this clinical trial
Patients with active brain metastases should be excluded from this clinical trial.
Patients with known brain metastases should be excluded from this clinical trial
Participants with known brain metastases should be excluded from this clinical trial
Patients with known brain metastases will be excluded from this clinical trial
Participants with known brain metastases should be excluded from this clinical trial
Patients with known brain metastases will be excluded from this clinical trial
Patients with known brain metastases should be excluded from this clinical trial
Participants with known brain metastases from solid tumors should be excluded from this clinical trial
Patients with known brain metastases should be excluded from this clinical trial
Patients with known brain metastases are excluded from this clinical trial; patients with primary brain tumors amenable to surgery are allowed on this protocol
Patients with known brain metastases should be excluded from this clinical trial
Participants with known brain metastases should be excluded from this clinical trial
Patients with known brain metastases should be excluded from this clinical trial; patients with brain metastases that are stable after >=  year after primary surgery or radiation will not be excluded
Patients with both brain and spine metastases will be excluded from the trial
Subject has known brain metastases; presence of brain metastases should be excluded from this clinical trial
Known brain metastases; patients with known brain metastases must be excluded from this clinical trial
Patients with known brain metastases should be excluded from this clinical trial
Subjects with known active brain metastases will be excluded from this clinical trial. Patients with brain metastases that have been treated and stable for >=  days following treatment will be eligible.
Have a history of or current evidence of intracranial disease; patients with brain metastases must be excluded from this clinical trial
Patients with known brain metastases should be excluded from this clinical trial
Patients with symptomatic or recurrent brain metastases should be excluded from this clinical trial
Patients with known, untreated or progressive brain metastases will be excluded from this clinical trial
Patients with known brain metastases should be excluded from this clinical trial
Patients with known brain metastases should be excluded from this clinical trial
Patients with known brain metastases should be excluded from this clinical trial
Patients with known brain metastases should be excluded from this clinical trial
Patients with known brain metastases should be excluded from this clinical trial
Subjects with known brain metastases should be excluded from this clinical trial
Patients with untreated brain metastases should be excluded from this clinical trial
Patients with known brain metastases should be excluded from this clinical trial
Patients with known brain metastases should be excluded from this clinical trial
Patients with known brain metastases should be excluded from this clinical trial
Subjects with known brain metastases should be excluded from this clinical trial
Patients with known active brain metastases, a history of seizure disorder, or other neurological disorders/dysfunction, should be excluded from this clinical trial
Participants with known brain metastases should be excluded from this clinical trial
Patients with known metastases would be excluded from this clinical trial
Patients with previously untreated and or symptomatic brain metastases are excluded from this clinical trial
Patients with known brain metastases should be excluded from this clinical trial
Participants with known brain metastases should be excluded from this clinical trial
Patients with known active or history of brain metastases should be excluded from this clinical trial
Participants with known brain metastases should be excluded from this clinical trial
Patients with known brain metastases should be excluded from this clinical trial
Participants with known brain metastases should be excluded from this clinical trial
Patients with known brain metastases should be excluded from this clinical trial
Patients with known brain metastases should be excluded from this clinical trial
Patients with known brain metastases should be excluded from early clinical trials
Patients with known brain metastases should be excluded from this clinical trial
Patients with known brain metastases should be excluded from this clinical trial
Patients with known brain metastases should be excluded from this clinical trial
Patients with known brain metastases with active symptoms or requiring anticonvulsive medications, or steroids should be excluded from this clinical trial
Participants with known brain metastases should be excluded from this clinical trial
Patients with known brain metastases should be excluded from this clinical trial
Patients with symptomatic brain metastases are excluded from this clinical trial
Patients with known brain metastases should be excluded from this clinical trial
Patients with known brain metastases are excluded from this clinical trial; patients with primary brain tumors amenable to surgery are allowed on this protocol
Patients with known brain metastases should be excluded from this clinical trial
Patients with untreated brain metastases should be excluded from this clinical trial
Patients with known brain metastases should be excluded from this clinical trial
Patients with known brain metastases should be excluded from this clinical trial
Participants with known brain metastases will be excluded from this clinical trial
Patients with known brain metastases should be excluded from this clinical trial
Patients with known brain metastases should be excluded from this clinical trial
Participants with known brain metastases should be excluded from this clinical trial
Patients with known brain metastases should be excluded from this clinical trial
Patients with known brain metastases should be excluded from this clinical trial
Patients with known brain metastases will be excluded from this clinical trial
Participants with known brain metastases should be excluded from this clinical trial
Patient must not have known brain metastases; patients with known brain metastases must be excluded from this clinical trial
Participants with known brain metastases should be excluded from this clinical trial; does not apply to group C
Patients with known brain metastases should be excluded from this clinical trial
Patients with known brain metastases should be excluded from this clinical trial
Patients with known brain metastases should be excluded from this clinical trial
Patients with known brain metastases should be excluded from this clinical trial
Patients with known brain metastases should be excluded from this clinical trial
Participants with known brain metastases should be excluded from this clinical trial
Patients with known brain metastases should be excluded from this clinical trial
Patients with active brain metastases should be excluded from this clinical trial except as noted above
Patients with known brain metastases will be excluded from this clinical trial
Known brain metastases; patients with known brain metastases must be excluded from this clinical trial
Patients with known brain metastases should be excluded from this clinical trial
Patients with known brain metastases will be excluded from this portion of the clinical trial (which will assess PFS and TTP)
Patients with primary brain cancer or known brain metastases should be excluded from this clinical trial
Patients with known brain metastases are excluded from this clinical trial
Patients with known brain metastases should be excluded from this clinical trial
Patients with known brain metastases should be excluded from this clinical trial
Patients with untreated brain metastases should be excluded from this clinical trial
Patients with known brain metastases will be excluded from this clinical trial
Patients with brain metastases should be excluded from this clinical trial except as noted above
Patients with known brain metastases should be excluded from this clinical trial
Patients with known brain metastases are excluded from this clinical trial
Patients with known brain metastases should be excluded from this clinical trial
Patients with known brain metastases should be excluded from this clinical trial
Participants with known brain metastases should be excluded from this clinical trial
Patients with untreated brain metastases, as determined by treating oncologist, will be excluded from this clinical trial; patients with treated brain metastasis are eligible for this trial, providing they have completed treatment at least one day prior to registration
Patients with known brain metastases will be excluded from this clinical trial
Participants with known metastatic disease should be excluded from this clinical trial
Patients with known brain metastases should be excluded from this clinical trial
Participants with known brain metastases should be excluded from this clinical trial
Patients with known symptomatic brain metastases should be excluded from this clinical trial
Participants with known brain metastases will be excluded from this clinical trial
Patients with known brain metastases should be excluded from this clinical trial
Participants with known brain metastases should be excluded from this clinical trial
Participants with known brain metastases should be excluded from this clinical trial
